Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price was up 0.4% on Monday . The company traded as high as $22.98 and last traded at $22.92. Approximately 8,233,778 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 40,799,289 shares. The stock had previously closed at $22.83.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $29.17.
Get Our Latest Research Report on Pfizer
Pfizer Stock Up 0.8%
The firm has a market cap of $130.82 billion, a P/E ratio of 16.32, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The firm's 50 day moving average is $23.65 and its two-hundred day moving average is $25.32. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.48%. Pfizer's dividend payout ratio is presently 124.64%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth $28,000. SCS Capital Management LLC acquired a new stake in Pfizer in the 1st quarter valued at $778,000. Semmax Financial Advisors Inc. lifted its position in Pfizer by 10.4% during the 1st quarter. Semmax Financial Advisors Inc. now owns 114,160 shares of the biopharmaceutical company's stock worth $2,893,000 after buying an additional 10,778 shares in the last quarter. Logan Capital Management Inc. boosted its stake in shares of Pfizer by 14.5% during the 1st quarter. Logan Capital Management Inc. now owns 602,162 shares of the biopharmaceutical company's stock worth $15,259,000 after buying an additional 76,174 shares during the last quarter. Finally, Faithward Advisors LLC raised its holdings in Pfizer by 59.4% during the first quarter. Faithward Advisors LLC now owns 12,314 shares of the biopharmaceutical company's stock worth $312,000 after acquiring an additional 4,588 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
